Kinaset Therapeutics
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Kinaset Therapeutics Closes $103M for Asthma Drug
Kinaset Therapeutics, developing an inhalable pan-JAK inhibitor for severe asthma, has raised $103 million in Series B funding.
The round was co-led by RA Capital Management and Forge Life Science Partners with participation from EQT Life Sciences, Vivo Capital, and Schroders Capital.
Key Highlights
- Inhalable pan-JAK inhibitor (frevecitinib)
- Targets severe asthma patients
- Minimal systemic side effects
Company Overview
Kinaset Therapeutics is developing frevecitinib, an inhalable pan-JAK inhibitor designed to target lung inflammation in severe asthma patients while minimizing systemic effects.
Company Info
Investors (4)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started